GE Healthcare Life Sciences, China, and Cellular Biomedicine Group Inc. (CBMG) have established a strategic research collaboration to co-develop certain high-quality industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing. In connection with the collaboration, a joint laboratory within CBMG's new Shanghai Zhangjiang GMP-facility will be established and dedicated to the joint research and development of a functionally integrated and automated immunotherapy cell preparation system.
CBMG and GE Healthcare Life Sciences, China, plan to develop state-of-the-art automated CAR-T and stem cell manufacturing capabilities that build upon the accreditation of CBMG's GMP facilities in Shanghai, Wuxi, and Beijing. The co-development activity will aim to standardize the delivery of cell manufacturing to potentially improve throughput, alleviate cost burdens and to minimize variability in cell production, which may increase the availability of engineered cells upon commercialization.
This partnership combines CBMG's scientific expertise in the manufacturing of CAR-T and stem cell production in China and GE Healthcare's renowned expertise in the design and development of innovative manufacturing technologies for the biopharmaceutical industry.